IL17A and enthesitis: IXE represents the main therapeutic choice in patients with CV risk events compared to anti-TNF and other anti-IL-17 (SEC-BIM) [30]; furthermore, the population treated with IXE has a mean age greater than 65 years [31]; it is also the most followed therapy in the treatment of patients with enthesitis and dactylitis compared to other anti-IL-17, anti-TNF and Jak inhibitors [32].